What is the official website of Taro Pharmaceuticals ?

The official website of Taro Pharmaceuticals is http://www.taro.com.

What is Taro Pharmaceuticals's cybersecurity risk score?

Taro Pharmaceuticals has an AI-generated cybersecurity risk score of 724 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Taro Pharmaceuticals experienced?

According to Rankiteo, Taro Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Taro Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Taro Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Taro Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Taro Pharmaceuticals is not certified under SOC 2 Type 1.

Does Taro Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Taro Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Taro Pharmaceuticals comply with GDPR ?

According to Rankiteo, Taro Pharmaceuticals is not listed as GDPR compliant.

Does Taro Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Taro Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Taro Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Taro Pharmaceuticals is not compliant with HIPAA regulations.

Does Taro Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Taro Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Taro Pharmaceuticals operate in ?

Taro Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Taro Pharmaceuticals have ?

Taro Pharmaceuticals employs approximately 1,518 people worldwide.

Does Taro Pharmaceuticals own any subsidiaries ?

Taro Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Taro Pharmaceuticals have ?

Taro Pharmaceuticals's official LinkedIn profile has approximately 40,119 followers.

What is the NAICS classification code for Taro Pharmaceuticals ?

Taro Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Taro Pharmaceuticals have a Crunchbase profile ?

No, Taro Pharmaceuticals does not have a profile on Crunchbase.

Does Taro Pharmaceuticals have a LinkedIn profile ?

Yes, Taro Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/taro-pharmaceuticals.

How many cybersecurity incidents has Taro Pharmaceuticals experienced ?

As of June 13, 2026, Rankiteo reports that Taro Pharmaceuticals has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Taro Pharmaceuticals have ?

Taro Pharmaceuticals has an estimated 5,686 peer or competitor companies worldwide.

What types of cybersecurity incidents has Taro Pharmaceuticals faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Taro Pharmaceuticals

Boost Score +25 with badge (5 left)

724

/1000

Moderate

749

/1000

Moderate

Taro Pharmaceuticals Vendor Cyber Rating & Cyber Score

taro.com

Add Your Compliance Badge

Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Taro Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Taro Pharmaceuticals

Taro Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Taro Pharmaceutical...

Breach

3/2023

TAR937072825

Loading…

A.I.

Taro Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Taro Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incident Types Taro Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incident History - Taro Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Taro Pharmaceuticals Subsidiaries

Taro Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.taro.com

Company Size: 1,518

Alchemee (formerly The Proactiv Company)Wellness and Fitness Services

TARO PHARMACEUTICALS CANADAPharmaceutical Manufacturing

Taro Pharmaceutical IndustriesPharmaceutical Manufacturing

Loading…

Taro Pharmaceuticals Similar Companies

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Loading…

NEWS

Taro Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 04, 2025 08:00 AM

Taro Pharmaceutical: How To Find & Own America's Greatest Opportunities

Drugmaker Taro Pharmaceutical was one of the rare exceptions of a stock that advanced while the S&P 500 descended into a bear market.

Read Article

October 28, 2025 07:00 AM

Sun Pharma Defeats Taro Investor Suit Over Take-Private Deal

A Taro Pharmaceutical Industries Ltd. investor failed to adequately allege the generic drugmaker or its then-suitor Sun Pharmaceutical...

Read Article

June 25, 2024 09:11 AM

Sun Pharma Completes $348 Mn Merger with Israel’s Taro Pharma

Sun Pharma successfully completes a mega MN merger with Israel's Taro Pharm, marking a significant move in the global pharmaceutical industry and further...

Read Article

January 21, 2024 08:00 AM

Taro to become wholly owned by Sun Pharma

India's Sun Pharmaceutical Industries will pay $43 per share for the 21.5% of Taro that it does not already own. Taro employs 1550 people in...

Read Article

January 18, 2024 08:00 AM

Sun Pharma to acquire Taro shares for $347.73m

Sun Pharmaceutical has signed a definitive merger agreement for the acquisition of all outstanding ordinary shares of Taro Pharmaceutical not currently owned...

Read Article

November 16, 2023 08:00 AM

US drops price-fixing case against former Taro Pharmaceutical executive

US prosecutors on Thursday asked a federal judge to dismiss charges in Pennsylvania against a former sales and marketing executive of Taro Pharmaceutical...

Read Article

May 27, 2023 07:00 AM

Taro Pharmaceuticals class action alleges company responsible for data breach

Taro Pharmaceuticals was negligent with its employees' data, leading to their private information being leaked in a cyberattack, a new class...

Read Article

March 06, 2023 08:00 AM

Sun Pharma suffers IT breach, says core systems not affected

Mumbai, India-based Sun Pharma disclosed an IT security breach. The company quickly isolated the affected systems and is investigating the situation.

Read Article

November 30, 2021 10:40 AM

Judge OKs $75M Sun, Taro Pharma generic drug price-fixing settlement

A judge signed off a settlement to end price-fixing claims against Sun Pharma and Taro Pharmaceutical Industries USA Inc.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-6676

SUMMARY

Heap buffer out-of-bounds write vulnerability in Avira Antivirus engine when scanning a malformed POSIX tar archive may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.27.12.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2026-12068

SUMMARY

Information disclosure vulnerability in Avira Password Manager when used with Mozilla Firefox may allow a remote attacker operating a cross-origin iframe to obtain credentials autofilled for the parent web page via incorrect autofill field selection. This issue affects Avira Password Manager when used with Mozilla Firefox on Windows, macOS, and Linux.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:N/A:N

Impact Score

Exploitability

2.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-9033

SUMMARY

Heap buffer out-of-bounds read vulnerability in Avira Antivirus engine when scanning a malformed PDF file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.76.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-9032

SUMMARY

Heap buffer out-of-bounds read vulnerability in Avira Antivirus engine when scanning a malformed Windows PE file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.98.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

CVE-2025-14098

SUMMARY

Heap buffer out-of-bounds write vulnerability due to integer overflow in Avira Antivirus engine when scanning a malformed MS-DOS executable file may allow Local Execution of Code or Denial-of-Service of the antivirus engine process. This issue affects Avira Antivirus on Windows, macOS, and Linux for engine builds before 8.3.70.104.

Published

Date2026-06-12

Updated

Date2026-06-12

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.gendigital.com/us/en/contact-us/security-advisories/

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…